We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

280 hedge funds and large institutions have $7.98B invested in BioMarin Pharmaceuticals in 2013 Q2 according to their latest regulatory filings, with 280 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

16% less call options, than puts

Call options by funds: $36.2M | Put options by funds: $43M

Holders
280
Holders Change
+280
Holders Change %
–
% of All Funds
9.14%
Holding in Top 10
7
Holding in Top 10 Change
+7
Holding in Top 10 Change %
% of All Funds
0.23%
New
280
Increased
–
Reduced
–
Closed
–
Calls
$36.2M
Puts
$43M
Net Calls
-$6.77M
Net Calls Change
-$6.77M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
HSBC Holdings
251
HSBC Holdings
United Kingdom
$109K +$122K +1,953 New
FIG
252
Fortress Investment Group
New York
$98K +$110K +1,763 New
TRCT
253
Tower Research Capital (TRC)
New York
$96K +$108K +1,728 New
Teacher Retirement System of Texas
254
Teacher Retirement System of Texas
Texas
$82K +$91.1K +1,462 New
US Bancorp
255
US Bancorp
Minnesota
$79K +$88.7K +1,424 New
CM
256
Castleark Management
Illinois
$63K +$70.1K +1,125 New
LTFS
257
Ladenburg Thalmann Financial Services
Florida
$53K +$57.3K +920 New
Robeco Institutional Asset Management
258
Robeco Institutional Asset Management
Netherlands
$43K +$48.3K +775 New
PC
259
Pier Capital
Connecticut
$40K +$44.9K +720 New
MUMSS
260
Mitsubishi UFJ Morgan Stanley Securities
Japan
$33K +$37.4K +600 New
OMCS
261
Old Mutual Customised Solutions
South Africa
$33K +$37.4K +600 New
SAMC
262
Shinko Asset Management Company
Japan
$33K +$37.4K +600 New
SFPIA
263
Stevens First Principles Investment Advisors
California
$22K +$24.9K +400 New
TCM
264
TimesSquare Capital Management
New York
$22K +$24.9K +400 New
MFS
265
MSI Financial Services
Massachusetts
$17K +$18.7K +300 New
PAS
266
Partnervest Advisory Services
California
$15K +$17.1K +275 New
HNB
267
Huntington National Bank
Ohio
$15K +$17.3K +277 New
Thrivent Financial for Lutherans
268
Thrivent Financial for Lutherans
Minnesota
$12.7K +$14.2M +228,343 New
MOACM
269
Mutual of America Capital Management
New York
$12K +$13.4K +215 New
HDIM
270
Hanson & Doremus Investment Management
Vermont
$11K +$12.5K +200 New
WT
271
Whittier Trust
California
$10K +$10.9K +175 New
EFSCE
272
Enterprise Financial Services Corp (EFSC)
Missouri
$6K +$6.17K +99 New
EU
273
Emory University
Georgia
$6K +$6.23K +100 New
Jones Financial Companies
274
Jones Financial Companies
Missouri
$6K +$7.17K +115 New
HR
275
Howe & Rusling
New York
$4K +$4.3K +69 New
8 9 10
11
12

BMRN Hedge Fund Activity: Q2 2013 in Review

280 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q2 2013, worth a combined $7.98B.

Buyers outnumbered sellers: 280 funds opened new BMRN positions and 0 closed out — a net gain of 280 holders — while 0 added to existing stakes and 0 trimmed.

  • 280 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $7.98B of BioMarin Pharmaceuticals stock for Q2 2013.
  • 280 funds opened new BioMarin Pharmaceuticals positions in Q2 2013 and 0 closed out, a net change of +280 holders.

Based on aggregated 13F filings for Q2 2013.